Technology strategy revealed: patterns and influences of patent-licensing behaviour in Japanese firms

Patterns of patent in-licensing and out-licensing are examined among Japanese firms in the pharmaceuticals and electronics industries. Sixty-five questionnaires and 24 interview-based cases provide insights into what influences the decisions to "make-or-buy" (in-license) knowledge assets and to "exploit-or-sell" (out-license) R&D outputs. Firm size and resources, the existing portfolio of technologies and ongoing exploitation strategies are all influential. Significant increases in in-licensing and out-licensing and associated changes in the management of intellectual property are also a response to changing competitive pressures and markets in Japan for both these sets of firms. Reciprocal technology-sharing agreements are evolving into more formalised relationships and firms are being pushed to improve their technology brokering capabilities. Looking beyond abstracted patent data, the study provides additional insights into the influences on strategic R&D selection as well as the general management dilemmas associated with the leveraging of intellectual assets, core competence selection and "markets versus hierarchies" decision making.

[1]  Robert E. Spekman,et al.  Alliances, External Technology Acquisition, and Discontinuous Technological Change , 1997 .

[2]  Jean O. Lanjouw,et al.  How to Count Patents and Value Intellectual Property: Uses of Patent Renewal and Application Data , 1996 .

[3]  Massimo Riccaboni,et al.  Technological change and network dynamics: Lessons from the pharmaceutical industry , 2001 .

[4]  O’D,et al.  Patent Breadth , Patent Life , and the Pace of Technological Progress , 1998 .

[5]  R. Grant Toward a Knowledge-Based Theory of the Firm,” Strategic Management Journal (17), pp. , 1996 .

[6]  S. Collinson Knowledge management capabilities in R&D: a UK‐‐Japan company comparison , 2001 .

[7]  Toru Yoshikawa,et al.  Technology development and acquisition strategy , 2003, Int. J. Technol. Manag..

[8]  Stefano Brusoni,et al.  The knowledge bases of the world’s largest pharmaceutical groups: what do patent citations to non-patent literature reveal? , 2005 .

[9]  Robert H. Pitkethly Intellectual property strategy in Japanese and UK companies: patent licensing decisions and learning opportunities , 2001 .

[10]  T. Neff,et al.  Survival of the Fittest , 1997 .

[11]  A. Arora,et al.  Licensing the market for technology , 2003 .

[12]  Margaret A. Peteraf The cornerstones of competitive advantage: A resource‐based view , 1993 .

[13]  David C. Wilson,et al.  Inertia in Japanese Organizations: Knowledge Management Routines and Failure to Innovate , 2006 .

[14]  Alfred Kleinknecht,et al.  Measuring R&D in Small Firms: How Much Are We Missing? , 1987 .

[15]  A. Jaffe Technological Opportunity and Spillovers of R&D: Evidence from Firms&Apos; Patents, Profits and Market Value , 1986 .

[16]  Alberto Torres Unlocking the Value of Intellectual Assets , 1999 .

[17]  A. Arora Licensing Tacit Knowledge: Intellectual Property Rights And The Market For Know-How , 1995 .

[18]  H. Odagiri Transaction costs and capabilities as determinants of the R&D boundaries of the firm: a case study of the ten largest pharmaceutical firms in Japan , 2003 .

[19]  Appropriation Of Returns From Technological Assets And The Values Of Patents And R&D In Japanese High-Tech Firms † , 1998 .

[20]  D. Teece,et al.  Managing Intellectual Capital: Licensing and Cross-Licensing in Semiconductors and Electronics , 1997 .

[21]  A. Arora,et al.  Markets for Technology and Their Implications for Corporate Strategy , 2000 .

[22]  A. Pakes,et al.  Patents and R&D at the Firm Level: A First Look , 1984 .

[23]  Wesley M. Cohen,et al.  R&D spillovers, patents and the incentives to innovate in Japan and the United States , 2002 .

[24]  B. Bowonder,et al.  The global pharmaceutical industry: changing competitive landscape , 2003, Int. J. Technol. Manag..

[25]  G. Pisano The R&D Boundaries of the Firm: An Empirical Analysis , 1990 .

[26]  James Taggart,et al.  The World Pharmaceutical Industry , 1993 .

[27]  Simon Kuznets,et al.  Inventive Activity: Problems of Definition and Measurement , 1962 .

[28]  D. Teece Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy , 1993 .

[29]  S. Winter,et al.  Appropriating the Returns from Industrial Research and Development , 1987 .

[30]  Masaaki Kotabe,et al.  A Comparative Study of U.S. and Japanese Patent Systems , 1992 .

[31]  D. Teece Strategies for Managing Knowledge Assets: the Role of Firm Structure and Industrial Context , 2000 .

[32]  D. Teece Capturing Value from Knowledge Assets: The New Economy, Markets for Know-How, and Intangible Assets , 1998 .

[33]  D. Jane Bower,et al.  A shift to external alliances for product development in the pharmaceutical industry , 1994 .

[34]  Padraig Dixon,et al.  The Economics of Intellectual Property: A Review to Identify Themes for Future Research , 2002 .

[35]  K. Pavitt Sectoral Patterns of Technical Change : Towards a Taxonomy and a Theory : Research Policy , 1984 .

[36]  O. Granstrand,et al.  Multi-Technology Corporations: Why They Have “Distributed” Rather Than “Distinctive Core” Competencies , 1997 .

[37]  D. Teece Managing Intellectual Capital: Organizational, Strategic, and Policy Dimensions , 2000 .

[38]  Z. Griliches Patent Statistics as Economic Indicators: a Survey , 1990 .

[39]  Mark Rogers,et al.  The value of innovation: The interaction of competition, R&D and IP , 2006 .

[40]  A. Pakes,et al.  The Rate of Obsolescence of Knowledge, Research Gestation Lags, and the Private Rate of Return to Research Resources , 1979 .

[41]  K. Pavitt,et al.  Knowledge Specialization, Organizational Coupling, and the Boundaries of the Firm: Why Do Firms Know More than They Make? , 2001 .

[42]  Alfred Kleinknecht,et al.  Determinants of innovation : the message from new indicators , 1996 .

[43]  Alfonso Gambardella Science and innovation , 1995 .